Coverage
-
March 04, 2022
Drug payors pressed a New Jersey federal judge Thursday not to let Celgene Corp. and parent Bristol-Myers Squibb Co. "delay justice and perpetuate the illegal conduct" preventing generic competition for two blockbuster cancer drugs, arguing that the drugmakers cannot use separate, "significantly different" litigation to justify a pause.
1 other articles on this case.
View all »